Follow
Giorgio Sesti
Giorgio Sesti
Full Professor of Internal Medicine-Sapienza University of Rome
Verified email at uniroma1.it
Title
Cited by
Cited by
Year
Basal insulin and cardiovascular and other outcomes in dysglycemia
OT Investigators
New England Journal of Medicine 367 (4), 319-328, 2012
20052012
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
JB Buse, J Rosenstock, G Sesti, WE Schmidt, E Montanya, JH Brett, ...
The Lancet 374 (9683), 39-47, 2009
19352009
Cardiovascular efficacy and safety of bococizumab in high-risk patients
SCO Investigators
New England Journal of Medicine 376 (16), 1527-1539, 2017
1746*2017
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet 292 (10157), 1519-1529, 2018
1319*2018
N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
OT Investigators
New England Journal of Medicine 367 (4), 309-318, 2012
10902012
Defects of the insulin receptor substrate (IRS) system in human metabolic disorders
G Sesti, M Federici, ML Hribal, D Lauro, P Sbraccia, R Lauro
The FASEB Journal 15 (12), 2099-2111, 2001
5012001
Pathophysiology of insulin resistance
G Sesti
Best practice & research Clinical endocrinology & metabolism 20 (4), 665-679, 2006
4912006
High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program
M Federici, M Hribal, L Perego, M Ranalli, Z Caradonna, C Perego, ...
Diabetes 50 (6), 1290-1301, 2001
4842001
Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells
M Federici, R Menghini, A Mauriello, ML Hribal, F Ferrelli, D Lauro, ...
Circulation 106 (4), 466-472, 2002
4522002
Uric acid and endothelial dysfunction in essential hypertension
C Zoccali, R Maio, F Mallamaci, G Sesti, F Perticone
Journal of the American Society of Nephrology 17 (5), 1466-1471, 2006
3732006
Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension
F Perticone, A Sciacqua, R Maio, M Perticone, R Maas, RH Boger, ...
Journal of the American College of Cardiology 46 (3), 518-523, 2005
3602005
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin …
O Vaccaro, M Masulli, A Nicolucci, E Bonora, S Del Prato, AP Maggioni, ...
The lancet Diabetes & endocrinology 5 (11), 887-897, 2017
2702017
Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in …
F Andreozzi, E Laratta, A Sciacqua, F Perticone, G Sesti
Circulation research 94 (9), 1211-1218, 2004
2652004
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome …
BJ Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L
Am Heart J 155 (1), 26-32, 2008
2522008
Pulse pressure and endothelial dysfunction in never-treated hypertensive patients
R Ceravolo, R Maio, A Pujia, A Sciacqua, G Ventura, MC Costa, G Sesti, ...
Journal of the American College of Cardiology 41 (10), 1753-1758, 2003
2472003
Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential
B Giovannone, M Lucia Scaldaferri, M Federici, O Porzio, D Lauro, ...
Diabetes/metabolism research and reviews 16 (6), 434-441, 2000
2262000
The Gly972→Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β cells
O Porzio, M Federici, ML Hribal, D Lauro, D Accili, R Lauro, P Borboni, ...
The Journal of clinical investigation 104 (3), 357-364, 1999
2141999
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
JB Buse, G Sesti, WE Schmidt, E Montanya, CT Chang, Y Xu, L Blonde, ...
Diabetes care 33 (6), 1300-1303, 2010
2132010
A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 …
MA Nauck, JR Petrie, G Sesti, E Mannucci, JP Courreges, ML Lindegaard, ...
Diabetes care 39 (2), 231-241, 2016
2122016
Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals
E Succurro, MA Marini, S Frontoni, ML Hribal, F Andreozzi, R Lauro, ...
Obesity 16 (8), 1881-1886, 2008
2112008
The system can't perform the operation now. Try again later.
Articles 1–20